Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 7/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822671 | 0.87 | AHR (0.52) | AHRCYP11B2CYP11B1NPC1RAB9A | |
| SCHEMBL30601172 | 0.81 | AHR (0.72) | AHRNPC1RAB9ASMN1; SMN2APP | |
| SCHEMBL14822546 | 0.81 | AHR (0.41) | AHRCYP11B2CYP11B1PIK3CDPIK3CG | |
| SCHEMBL15938425 | 0.81 | CYP11B2 (0.40) | AHRCYP11B2CYP11B1ADORA3ADORA1 | |
| SCHEMBL15937966 | 0.77 | AHR (0.58) | AHRSMN1; SMN2DYRK1APIK3CAPIK3CG | |
| SCHEMBL30601212 | 0.77 | AHR (0.81) | AHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15938078 | 0.75 | AHR (0.44) | AHRCYP11B2CYP11B1PIK3CDPIK3CG | |
| SCHEMBL14810251 | 0.75 | AHR (0.59) | AHRCYP11B2CYP11B1NPC1RAB9A | |
| SCHEMBL14822670 | 0.73 | AHR (0.47) | AHRCYP11B2CYP11B1NPC1RAB9A | |
| SCHEMBL14822660 | 0.72 | AHR (0.49) | AHRCYP11B2CYP11B1SMN1; SMN2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757883-B1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2757883-B1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| US-9567333-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567333-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567333-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-02-11 | — | — | US | disclosed |
| US-9193724-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193724-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193724-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| WO-2013043520-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, HSD11B1, CYP17A1 | AHR 2535/4885CYP11B2 4/4885CYP11B1 6/4885 |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, CYP11B2 | AHR 2758/4885CYP11B2 3/4885CYP11B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.